Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone on HDL apolipoprotein A-I (apoA-I) and apoA-I...

Full description

Bibliographic Details
Main Authors: John S. Millar, Katsunori Ikewaki, LeAnne T. Bloedon, Megan L. Wolfe, Philippe O. Szapary, Daniel J. Rader
Format: Article
Language:English
Published: Elsevier 2011-01-01
Series:Journal of Lipid Research
Subjects:
apolipoprotein A-I
stable isotope
thiazolidinedione
lipoprotein kinetics
high density lipoprotein
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520405048

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520405048

Similar Items